Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (9): 957-959.DOI: 10.3969/j.issn.1673-8640.2020.09.024
Previous Articles Next Articles
Received:2019-06-03
Online:2020-09-30
Published:2020-09-29
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.09.024
| 组别 | 例数 | 肌电图 | 主要临床症状 | |||||
|---|---|---|---|---|---|---|---|---|
| 肌源性损伤 | 正常 | 未检测 | 肌无力 | 肌痛 | 两者兼有 | |||
| 暴露组 | 23 | 17（73.9） | 4（17.4） | 2（8.69） | 6（26.09） | 3（13.04） | 14（60.87） | |
| 非暴露组 | 23 | 15（65.2） | 6（26.1） | 2（8.69） | 5（21.74） | 2（8.69） | 16（69.57） | |
| χ2值 | 0.525 | 0.424 | ||||||
| P值 | 0.769 | 0.809 | ||||||
| 组别 | 例数 | 肌电图 | 主要临床症状 | |||||
|---|---|---|---|---|---|---|---|---|
| 肌源性损伤 | 正常 | 未检测 | 肌无力 | 肌痛 | 两者兼有 | |||
| 暴露组 | 23 | 17（73.9） | 4（17.4） | 2（8.69） | 6（26.09） | 3（13.04） | 14（60.87） | |
| 非暴露组 | 23 | 15（65.2） | 6（26.1） | 2（8.69） | 5（21.74） | 2（8.69） | 16（69.57） | |
| χ2值 | 0.525 | 0.424 | ||||||
| P值 | 0.769 | 0.809 | ||||||
| 组别 | 例数 | MHC-Ⅰ/例 | CK /（U/L） | 抗HMGCR抗体阳性/ [例（%）] | |||
|---|---|---|---|---|---|---|---|
| - | + | ++ | |||||
| 暴露组 | 23 | 2 | 4 | 9 | 8 | 1 644.83±1 611.04 | 19（82.61） |
| 非暴露组 | 23 | 1 | 6 | 11 | 5 | 1 479.94±762.13 | 3（13.04） |
| 统计值 | 2.301 | 0.443 | 22.303 | ||||
| P值 | 0.231 | 0.662 | 0.000 | ||||
| 组别 | 例数 | MHC-Ⅰ/例 | CK /（U/L） | 抗HMGCR抗体阳性/ [例（%）] | |||
|---|---|---|---|---|---|---|---|
| - | + | ++ | |||||
| 暴露组 | 23 | 2 | 4 | 9 | 8 | 1 644.83±1 611.04 | 19（82.61） |
| 非暴露组 | 23 | 1 | 6 | 11 | 5 | 1 479.94±762.13 | 3（13.04） |
| 统计值 | 2.301 | 0.443 | 22.303 | ||||
| P值 | 0.231 | 0.662 | 0.000 | ||||
| [1] | 朱虎成,陈春梅,赵德,等. 他汀类药物导致的肌病及其致病机制研究进展[J]. 中国抗生素杂志,2011,36(9):651-653. |
| [2] | 秦峰,蔡辉. 他汀类药物多效性研究进展[J]. 临床神经病学杂志,2017,30(1):76-78. |
| [3] | 韩家豪,刘添甜,高燕. 他汀类药物相关肌病及其机制研究[J]. 中华老年心脑血管病杂志,2018,20(11):1221-1223. |
| [4] | 宋媛媛,杜丽萍,王蕴怡,等. 他汀类药物在临床应用中的不良反应及产生机制[J]. 中国生化药物杂志,2016,37(1):174-177. |
| [5] | ALSHEHRI A,CHOKSI R,BUCELLI R,et al.Myopathy with anti-HMGCR antibodies:perimysium and myofiber pathology[J]. Neurol Neuroimmunol Neuroinflamm,2015,2(4):e124. |
| [6] | HOOGENDIJK J E,AMATO A A,LECKY B R,et al.119th ENMC international workshop:trial design in adult idiopathic inflammatory myopathies,with the exception of inclusion body myositis,10-12 October 2003,Naarden,the Netherlands[J]. Neuromuscul Disord,2004,14(5):337-345. |
| [7] | 黄一宁. 他汀类调脂药神经肌肉系统不良反应[J]. 中国现代神经疾病杂志,2016,16(9):545-547. |
| [8] | NEEDHAM M.Necrotising autoimmune myopathy-clinical aspects[J]. Pathology,2015,47(S1):S42. |
| [9] | 焦宇琼,林洁,蔡爽,等. 他汀类药物相关抗HMGCR抗体介导坏死性肌病的研究进展[J]. 中国临床神经科学,2017,25(2):191-197. |
| [10] | KITZMILLER J P,GROEN D K,PHELPS M A,et al.Pharmacogenomic testing:relevance in medical practice: why drugs work in some patients but not in others[J]. Cleve Clin J Med,2011,78(4):243-257. |
| [11] | MAGHSOODI N,WIERZBICKI A S.Statin myopathy:over-rated and under-treated?[J]. Curr Opin Cardiol,2016,31(4):417-425. |
| [12] | MUSSET L,ALLENBACH Y,BENVENISTE O,et al.Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies:a history of statins and experience from a large international multi-center study[J]. Autoimmun Rev,2016,15(10):983-993. |
| [13] | SHOVMAN O,GILBURD B,CHAYAT C,et al.Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure[J]. Immunol Res,2017,65(1):276-281. |
| [14] | BERGUA C,CHIAVELLI H,ALLENBACH Y,et al.In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy[J]. Ann Rheum Dis,2019,78(1):131-139. |
| [1] | TANG Qingqin, QIAO Longwei, YIN Jingping, ZHANG Sheng, FENG Bin, LIANG Yuting. Correlation of peripheral blood monocyte count and serum anti-phospholipase A2 receptor antibody in patients with nephrotic syndrome [J]. Laboratory Medicine, 2023, 38(7): 647-652. |
| [2] | WANG Haiping, LI He. BISAP score combined with serum sRAGE for predicting hyperlipidemic acute pancreatitis severity and short-term prognosis [J]. Laboratory Medicine, 2023, 38(7): 653-658. |
| [3] | WU Jie, LI Zenghe, CHEN Baorong, KONG Xujing. Establishment of traceable steroid hormone standard curve for dried blood spot samples [J]. Laboratory Medicine, 2023, 38(5): 489-493. |
| [4] | . [J]. Laboratory Medicine, 2023, 38(3): 291-293. |
| [5] | . [J]. Laboratory Medicine, 2023, 38(1): 100-102. |
| [6] | . [J]. Laboratory Medicine, 2022, 37(9): 892-893. |
| [7] | SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318. |
| [8] | SUN Xiaodan, XU Jing, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Inhibitory effects of antiestrogen on the proliferation and CCL2 expression of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(4): 319-324. |
| [9] | CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341. |
| [10] | ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355. |
| [11] | ZHANG Zhibin, YANG Wanyong, RUAN Fuwang, WEN Qinghui. Roles of total IgE,sIgE and 25（OH）D in the evaluation of infant atopic dermatitis [J]. Laboratory Medicine, 2022, 37(3): 217-220. |
| [12] | . [J]. Laboratory Medicine, 2021, 36(12): 1264-1266. |
| [13] | QIU Fang, ZHU Ping, JIANG Peng, WANG Chan. Relation between anti-gp210 antibody,anti-sp100 antibody and ALBI score in patients with primary biliary cholangitis [J]. Laboratory Medicine, 2021, 36(11): 1106-1109. |
| [14] | . [J]. Laboratory Medicine, 2021, 36(9): 925-928. |
| [15] | LIU Yang, ZHANG Zhiping, PENG Daorong, SONG Liuwei, GE Shengxiang, HAO Xiaoke, LIU Jiayun. Establishment and performance evaluation of chemiluminescent microparticle immunoassay for the determination of high concentration HbsAg [J]. Laboratory Medicine, 2020, 35(10): 1056-1061. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
